Market news — every asset we track

Assets

ORMP

Type 2 Diabetes Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Ionis Pharma, Eli Lilly, Oramed Pharma, AstraZeneca, Novo Nordisk, Jiangsu

Sep 25Barchart.com

ORMP

Oramed Pharmaceuticals shareholders approve board, stock plan amendment at annual meeting

Sep 17Investing.com

ORMP

Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More (ORMP)

Sep 11Seeking Alpha

Nano Dimension Appoints Nadav Kidron to Board of Directors to Chair Strategy and Capital Allocation Committee

WALTHAM, Mass., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Nano Dimension Ltd. (Nasdaq: NNDM) (“Nano Dimension,” “Nano,” or the “Company”) today announced the appointment of Nadav Kidron to its Board of Directors (the “Board”). As part of the Board’s ongoing strategic review, led by Chairman Phillip Borenstein, the Board intends to establish a Strategy and Capital Allocation Committee to support the Board’s evaluation of capital allocation alternatives, potential returns of excess capital to shareholders

Aug 17Yahoo Finance

NNDM

ORMP

Oramed: Q2 Earnings Snapshot

Aug 10Yahoo Finance

ORMP

This is the newest page. Registered accounts read further back.